scholarly journals Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine

Vaccines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 82 ◽  
Author(s):  
Els van Westen ◽  
Mirjam Knol ◽  
Alienke Wijmenga-Monsuur ◽  
Irina Tcherniaeva ◽  
Leo Schouls ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Pneumococcal Disease ◽  
Booster Dose ◽  
Multiple Time ◽  
Igg Antibody ◽  
Primary Series ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Antibody Levels ◽  
Antibody Kinetics

The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease. We compared the levels of 10-valent (PCV10) and 13-valent (PCV13) pneumococcal vaccine induced serum IgG antibodies at multiple time points after primary vaccinations. Data from two separate studies both performed in the Netherlands in infants vaccinated at 2, 3, and 4 months of age with either PCV10 or PCV13 were compared. Antibody levels were measured at 5, 8, and 11 months of age, during the interval between the primary immunization series and the 11-months booster dose. Serotype-specific IgG levels were determined by multiplex immunoassay. Although antibody kinetics showed significant variation between serotypes and between vaccines for the majority of the 10 shared serotypes, i.e., 1, 5, 7F, 9V, 14, 18C, and 23F, antibody concentrations were sufficiently high for both vaccines, immediately after the primary series and throughout the whole period until the booster dose. In contrast, for serotypes 4 and 19F in the PCV10 group and for serotypes 4 and 6B in the PCV13 group, IgG antibody concentrations already come within reach of the frequently used seroprotection level of 0.35 μg/mL immediately after the primary series at the five month time point and/or at eight months. This paper addresses the importance of revealing differences in serotype-specific and pneumococcal vaccine-dependent IgG antibody patterns during the interval between the primary series and the booster dose, an age period with a high IPD incidence. Trial registration: www.trialregister.nl NTR3069 and NTR2316.

scholarly journals Assessment of S1, S2 and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays

2021 ◽  
Author(s):  
Georg Semmler ◽  
Marianna Theresia Traugott ◽  
Marianne Graninger ◽  
Wolfgang Hoepler ◽  
Tamara Seitz ◽  
...  
Keyword(s):  
Rapid Test ◽  
Tracheal Aspirate ◽  
Target Antigen ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Detection Rates ◽  
Specific Igg ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Specific Igg Antibodies

In this study, we comprehensively analyzed multispecific antibody kinetics of different immunoglobulins in hospitalized patients with acute SARS-CoV-2 infection. Three-hundred-fifty-four blood samples longitudinally obtained from 81 IgG seroconverting CoVID-19 patients were quantified for spike (S)1, S2, and nucleocapsid protein (NCP)- specific IgM, IgA, IgG, and total Ig antibodies using a microarray, eleven different ELISAs/CLIAs, and one rapid test by seven manufacturers. The assays’ specificity was assessed in 130 non-CoVID19 pneumonia patients. Using the microarray, NCP-specific IgA and IgG antibodies continuously displayed higher detection rates during acute CoVID-19 than S1- and S2-specific ones. S1-specific IgG antibodies, however, reached higher peak values. Until the 26th-day post symptom onset, all patients developed IgG responses against S1, S2, and NCP, respectively. Although detection rates by ELISAs/CLIAs generally resembled those of the microarray, corresponding to the target antigen, sensitivities and specificities varied among all tests. Notably, patients with more severe CoVID-19 displayed higher IgG and IgA levels, but this difference was mainly observed with S1-specific immunoassays. In patients with high SARS-CoV-2 levels in the lower respiratory tract, we observed high detection rates of IgG and total Ig immunoassays with a particular rise of S1-specific IgG antibodies when viral concentrations in the tracheal aspirate subsequently declined over time. In summary, our study demonstrates that differences in sensitivity among commercial immunoassays during acute SARS-CoV-2 infection are only partly related to the target antigen. Importantly, our data indicate that NCP-specific IgA and IgG antibodies are detected earlier, while higher S1-specific IgA antibody levels occur in severely ill patients.

Measurement of Specific IgG Antibody Levels in Serum of Patients on Regimes Comprising High Total Dose Beta-Lactam Therapy

1986 ◽  
Vol 79 (4) ◽  
pp. 344-348 ◽  
Author(s):  
D. Lee ◽  
Janet M. Dewdney ◽  
R.G. Edwards ◽  
K.A. Neftel ◽  
M. Wälti
Keyword(s):  
Total Dose ◽  
Beta Lactam ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels ◽  
High Total Dose

scholarly journals An Uncommon Site of Streptococcus pneumoniae Colonization Leading to Recurrent Pneumococcal Disease

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Parham Sendi ◽  
Eva Maria Moser Schaub ◽  
Konstantinos Nirgianakis ◽  
Lucy J. Hathaway ◽  
Pascal Bittel ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Pneumococcal Vaccine ◽  
Pneumococcal Disease ◽  
Contraceptive Device ◽  
Source Of Infection ◽  
Vaginal Colonization ◽  
Intrauterine Contraceptive ◽  
Conjugate Pneumococcal Vaccine ◽  
Antibody Levels

Abstract This report describes a case of relapsing pneumococcal peritonitis. The postulated source of infection was vaginal colonization and secondary adherence of pneumococci to an intrauterine contraceptive device. After immunization with a conjugate pneumococcal vaccine, her antibody levels were observed. She remained infection free at the 2-year follow-up investigation.

IgG Levels after Treatment with Antigen Vials Based on the Scratch Testing, Intradermal Testing, Modified RAST Testing

1986 ◽  
Vol 95 (3_part_1) ◽  
pp. 307-311 ◽  
Author(s):  
Richard J. Trevino
Keyword(s):  
Scratch Testing ◽  
Igg Antibody ◽  
Intradermal Testing ◽  
Blocking Antibody ◽  
Multiple Treatment ◽  
End Point ◽  
Specific Igg ◽  
Inhalant Allergens ◽  
Inhalant Allergy ◽  
Antibody Levels

In this study, there were three groups of patients—each group consisting of four patients. The first group had been skin tested by the scratch method, the second group was skin tested by the end point titration intradermal method, and the third group had been tested for inhalant allergy by the modified RAST technique. All of them had multiple treatment vials made, dependent on the type of testing they had, and the vials all included the ten inhalants that were tested for. All patients had been treated for a year with weekly immunotherapy injections. Specific IgG levels, blocking antibody levels to the ten inhalant allergens, were determined. The results were that the patients who had been scratch tested had the lowest levels of specific IgG blocking antibody—while both intradermal end point titration and modified RAST testing had much higher elevations of blocking IgG antibody, with the RAST having the highest. It is concluded that, since the treatment vials prepared after scratch testing of all the antigens are at the same concentration, there are many antigens that are not given in adequate amounts to cause a good IgG response whereas, by calibrating the concentrations of antigens in the intradermal titration and the modified RAST testing, all the antigens are being injected in sufficient quantities to get a good blocking antibody response.

scholarly journals Lymphocyte Subsets and Specific IgG Antibody Levels in Clindamycin-Treated and Untreated Dogs Experimentally Infected with Babesia gibsoni

2003 ◽  
Vol 65 (5) ◽  
pp. 579-584 ◽  
Author(s):  
Retno WULANSARI ◽  
Agus WIJAYA ◽  
Hitoshi ANO ◽  
Yoichiro HORII ◽  
Susumu MAKIMURA
Keyword(s):  
Lymphocyte Subsets ◽  
Babesia Gibsoni ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels

scholarly journals Long-term Specific IgG Response to SARS-CoV-2 Nucleocapsid Protein in Recovered COVID-19 Patients

2021 ◽  
Author(s):  
Jira Chansaenroj ◽  
Ritthideach Yorsaeng ◽  
Nawarat Posuwan ◽  
Jiratchaya Puenpa ◽  
Nasamon Wanlapakorn ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Multiple Time ◽  
Serum Samples ◽  
Asymptomatic Group ◽  
Seropositivity Rate ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Respiratory Specimens

Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N=302) or multiple time points (N=229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti‑N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P<0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P<0.01), 9 months (P=0.04), and 12 months (P=0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r=0.192, P<0.01) but negatively correlated with interval between symptom onset and blood sampling (r=−0.567, P<0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.

scholarly journals Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jira Chansaenroj ◽  
Ritthideach Yorsaeng ◽  
Nawarat Posuwan ◽  
Jiratchaya Puenpa ◽  
Nasamon Wanlapakorn ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Multiple Time ◽  
Serum Samples ◽  
Asymptomatic Group ◽  
Seropositivity Rate ◽  
Chemiluminescent Microparticle Immunoassay ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Respiratory Specimens

AbstractThis study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r =  − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.

scholarly journals SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 in the UK general population

2021 ◽  
Author(s):  
Jia Wei ◽  
Koen B. Pouwels ◽  
Nicole Stoesser ◽  
Philippa C. Matthews ◽  
Ian Diamond ◽  
...  
Keyword(s):  
General Population ◽  
Booster Dose ◽  
Peak Level ◽  
Antibody Responses ◽  
Short Term ◽  
Igg Antibody ◽  
The Uk ◽  
Dosing Intervals ◽  
Antibody Levels ◽  
Prior Infection

We investigated anti-spike IgG antibody responses following second doses of ChAdOx1 or BNT162b2 SARS-CoV-2 vaccines in the UK general population. In 186,527 individuals, we found significant boosting of anti-spike IgG by second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOX1. Antibody levels declined faster at older ages than younger ages with BNT162b2, but were similar across ages with ChAdOX1. With both vaccines, prior infection significantly increased antibody peak level and half-life. Protection was estimated to last for 0.5-1 year after ChAdOx1 and >1 year after BNT162b2, but could be reduced against emerging variants. Reducing the dosing interval to 8 weeks for both vaccines or further to 3 weeks for BNT162b2 may help increase short-term protection against the Delta variant. A third booster dose may be needed, prioritised to more vulnerable people.

scholarly journals Immunogenicity of 10-valent pneumococcal conjugate vaccine among infants attending Mbagathi District Hospital, Kenya

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 165
Author(s):  
Michael Walekhwa ◽  
Margaret Muturi ◽  
Elizabeth Bukusi
Keyword(s):  
Chronic Illness ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
District Hospital ◽  
Maternal Diet ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Specific Igg ◽  
Socio Demographic Factors ◽  
Antibody Levels

Introduction: This study aimed to determine the serum concentration of IgG antibodies as an indicator of immunogenicity, alongside the assessment of socio-demographic factors that affect IgG antibody levels in infants immunized with 10-valent pneumococcal conjugate vaccine (PCV-10) at the Mbagathi District Hospital in Kenya.Materials and methods: This cross-sectional study measured serum IgG antibodies among infants who had completed a 3-dose course of PCV-10. IgG antibodies to pneumococcal serotype-specific capsular polysaccharide were measured through enzyme-linked immunosorbent assay (ELISA).Results: The majority (83%) of infants who completed the required dose of pneumococcal conjugate vaccine had serum titres of pneumococcal disease- (PD) specific IgG antibodies of between 0.34 mg/dl and 0.36 mg/dl. 4% of infants had serum titres of 0.30 mg/dl to 0.33 mg/dl. The remaining 2% had IgG antibody titres of either ≤0.25 mg/dl, or between 0.25 mg/dl to 0.29 mg/dl. Additionally, there was multi-collinearity among the IgG antibody levels of the infants studied and several variables that had an effect on these levels. These included: alcohol consumption by infants’ biological mothers during pregnancy (r =.595, p ≤ 0.05); maternal diet during pregnancy (r =.137, p ≤ 0.05); breastfeeding frequency (r =.220, p ≤ 0.05); proximity to other children (r =.133, p ≤ 0.05); child hospitalization (r =.131, p ≤ 0.05) and chronic illness (r =.154, p ≤0.01).Conclusion: PCV-10 is immunogenic against PD four weeks after completion of 3-doses among the infants attending the Child Welfare clinic at the Mbagathi District Hospital in Kenya. Socio-demographic factors which include consumption of alcoholic drinks by infant’s biological mother during pregnancy and study infant chronic illness negatively affect the development of PD specific IgG. A balanced maternal diet during pregnancy and a breastfeeding frequency superior to three times per day have a significant positive effect on serum pneumococcal IgG levels among infants.

Sign in / Sign up

Export Citation Format

Share Document